CYP2C19 gene variants and major depressive disorder: integrative review
Variantes genéticas do gene CYP2C19 e o transtorno depressivo maior: revisão integrativa
Resumo
Major depressive disorder (MDD) is a multifactorial condition common in the general population, treated with different antidepressants. Several genes are involved in the metabolism of these antidepressants, including CYP2C19. Consequently, functional polymorphisms in these genes affect these drugs' metabolism. Through an integrative review, this research aimed to verify the CYP2C19 gene polymorphisms' influence on antidepressant metabolism, evaluate their frequency in patients affected by MDD, verify clinical and demographic characteristics of studied populations, and identify possible associations of this gene with MDD. The database used to search for articles was Biblioteca Virtual em Saúde - BVS, and four articles were selected. Polymorphisms in the CYP2C19 gene may contribute to the metabolism of some antidepressants, such as citalopram, but not others, such as venlafaxine and sertraline. Interestingly, the drug sertraline can influence the levels of lipid profile parameters. In addition, some polymorphisms may be relatively frequent depending on the populations, such as Asians. No CYP2C19 polymorphisms associated with MDD development were observed.
Downloads
Referências
ANDRADE C. Relative Efficacy and Acceptability of Antidepressant Drugs in Adults With Major Depressive Disorder: Commentary on a Network Meta-Analysis. 2018. The Journal of Clinical Psychiatry. 79(2), 18f12254. https://doi.org/10.4088/JCP.18f12254
ATHIRA, Kaipuzha V. et al. An overview of the heterogeneity of major depressive disorder: current knowledge and future prospective. Current Neuropharmacology, v. 18, n. 3, p. 168-187, 2020. https://doi.org/10.2174/1570159X17666191001142934
BERRIOS, German E. Melancolia e depressão durante o século XIX: uma história conceitual. Revista Latinoamericana de Psicopatologia Fundamental, v. 15, p. 590-608, 2012. https://doi.org/10.1590/S1415-47142012000300011
CANTILINO, Amaury; MONTEIRO, Denilson. Psiquiatria Clínica: Um Guia Para Médicos E Profissionais De Saúde Mental. 1 Ed. Rio De Janeiro: Medbook, 2017. Cap 7.
CHEN, Lingling et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics, v. 9, n. 6, p. 691–702, 2008. https://doi.org/10.2217/14622416.9.6.691
CHEN, Qi et al. Advances in human cytochrome p450 and personalized medicine. Current Drug Metabolism, v. 12, n. 5, p. 436-444, 2011. https://doi.org/10.2174/138920011795495259
DUCONGE, Jorge et al. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. Puerto Rico Health Sciences Journal, v. 27, n. 4, p. 357, 2008. Disponível Em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748933/. Acessado Em: 31 De Mai. 2023.
FERGUSON, Charmaine S.; TYNDALE, Rachel F. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in Pharmacological Sciences, v. 32, n. 12, p. 708-714, 2011. https://doi.org/10.1016/j.tips.2011.08.005
GUTIÉRREZ-ROJAS, Luis et al. Prevalence and correlates of major depressive disorder: a systematic review. Brazilian Journal of Psychiatry, v. 42, p. 657-672, 2020. http://doi.org/10.1590/1516-4446-2020-0650
ISHII, Genki et al. CYP2C19 polymorphism affects personality traits of Japanese females. Neuroscience Letters, v. 411, n. 1, p. 77-80, 2007. https://doi.org/10.1016/j.neulet.2006.10.012
MALHI, Gin S.; MANN, J. John. Depression. The Lancet, v. 392, n. 10161, p. 2299-2312, 2018. https://doi.org/10.1016/S0140-6736(18)31948-2
MORENO, Ricardo Alberto; MORENO, Doris Hupfeld; SOARES, Márcia Britto De Macedo. Psicofarmacologia De Antidepressivos. Brazilian Journal Of Psychiatry, 1999, 21: 24-40. https://doi.org/10.1590/S1516-44461999000500006
MRAZEK, David A. et al. CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, v. 21, n. 1, p. 1, 2011. https://doi.org/10.1097/FPC.0b013e328340bc5a
NELSON, David L; COX, Michael M. Princípios De Bioquímica De Lehninger. 7 Porto Alegre: Artmed, 2019. Cap 21.
NUSSBAUM, Robert; MCINNES, Roderick R.; WILLARD, Huntington F. Thompson & Thompson Genética Médica. 8 Ed. Rio De Janeiro: Elsevier, 2016. Cap. 4.
OTTE, Christian, Et Al. Major Depressive Disorder. Nature Reviews Disease Primers, 2016, 2.1:1-20. https://doi.org/10.1038/nrdp.2016.65
PENNER-GOEKE, Signe; BINDER, Elisabeth B. Epigenetics And Depression. Dialogues In Clinical Neuroscience, 2022. https://doi.org/10.31887/DCNS.2019.21.4/ebinder
PIATKOV, Irina; JONES, Trudi; VAN VUUREN, Rainei J. Suicide cases and venlafaxine. Acta Neuropsychiatrica, v. 23, n. 4, p. 156-160, 2011. https://doi.org/10.1111/j.1601-5215.2011.00566.x
QUEVEDO, Joao; NARDI, Antonio; SILVA, Antônio. Depressão: Teoria E Clínica. 2ed. Artmed. 2018. Cap 1.
RUAÑO, Gualberto et al. Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomarkers in Medicine, v. 5, n. 4, p. 439-449, 2011. https://doi.org/10.2217/bmm.11.33
SCHAEFER, G. Bradley; JAMES, N. Thompson. Jr. Genética Médica. 1ed. Porto Alegre. Amgh, 2015. Cap 7.
SINGH, V. Et Al. Single-Nucleotide Polymorphisms In Genes Encoding Toll-Like Receptor -2, -3, -4, And -9 In A Case-Control Study With Bladder Cancer Susceptibility In A North Indian Population. Archives Of Medical Research, V. 44, N. 1, P. 54–61, Jan. 2013. https://doi.org/10.1016/j.arcmed.2012.10.008
UCKUN, Z. et al. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics, v. 40, n. 6, p. 672-679, 2015. https://doi.org/10.1111/jcpt.12320
WORLD HEALTH ORGANIZATION. Depressive Disorder (Depression). Atualizado Em: 31 De Mar. 2023. Disponível Em: Https://Www.Who.Int/News-Room/Fact-Sheets/Detail/Depression. Acessado Em: 31 De Mai. 2023.
YANG, Rui et al. Sex difference in lipid levels in first-diagnosed drug-naive depression patients: A case-control and 12-weeks follow-up study. The World Journal of Biological Psychiatry, v. 23, n. 3, p. 228-235, 2022. https://doi.org/10.1080/15622975.2021.1961500
YUCE-ARTUN, Nazan et al. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. International Journal of Clinical Pharmacy, v. 38, p. 388-394, 2016. https://doi.org/10.1007/s11096-016-0259-8
ZHANG, Naixing et al. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population. Psychiatric Genetics, v. 30, n. 1, p. 30-33, 2020. https://doi.org/10.1097/YPG.0000000000000246
ZIEBA, Agata; MATOSIUK, Dariusz; KACZOR, Agnieszka A. The Role Of Genetics In The Development And Pharmacotherapy Of Depression And Its Impact On Drug Discovery. International Journal Of Molecular Sciences, 2023, 24.3: 2946. https://doi.org/10.3390/ijms24032946
